Artera and Tempus Partner to Expand Access to AI-Powered Prostate Cancer Risk Stratification
Artera, a leader in multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has entered into an exclusive collaboration with Tempus, a technology-driven precision medicine company, to expand access to the ArteraAI Prostate Test. This AI-powered test provides risk stratification insights to help personalize prostate cancer treatment. Leveraging Tempus’ network, which reaches more than half of practicing oncologists in the U.S., the partnership aims to make the test widely available across cancer centers.
The ArteraAI Prostate Test is the first AI-enabled test capable of delivering both prognostic and predictive insights for patients with localized prostate cancer. It provides actionable information within 1-2 days of receiving a patient’s specimen, assisting clinicians in optimizing treatment strategies. Notably, it is the only AI-based risk stratification tool recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer and the only test validated for predicting responses to short-term androgen deprivation therapy (ADT).
“We are excited to collaborate with Artera to expand access to its prostate cancer test,” said Dr. Ezra Cohen, Chief Medical Officer at Tempus. “Treatment decisions for localized prostate cancer require balancing risks and benefits. By working together, we can empower clinicians with critical insights, ensuring patients receive personalized, data-driven care.”
The partnership underscores both companies’ commitment to advancing precision medicine and improving outcomes in oncology. Andre Esteva, CEO and co-founder of Artera, stated, “Our collaboration with Tempus is a testament to the dedication and innovation of our team in transforming cancer care. With Tempus’ vast expertise and reach, we are poised to make a significant impact on patient outcomes and the future of precision oncology.”
Artera plans to expand its AI-driven portfolio, introducing additional predictive tests for other cancer types in the future.
